Last updated: February 19, 2026
PREVNAR 13, a pneumococcal 13-valent conjugate vaccine developed by Pfizer Inc., is a leading product in the vaccine market. Its market performance is influenced by factors including the competitive landscape, regulatory approvals, vaccination guidelines, and the ongoing threat of pneumococcal disease. The vaccine has achieved substantial commercial success, contributing significantly to Pfizer's revenue.
What is the current market position of PREVNAR 13?
PREVNAR 13 holds a dominant position in the pneumococcal vaccine market. It is approved for use in both pediatric and adult populations, addressing the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 22F. This broad serotype coverage differentiates it from earlier pneumococcal vaccines.
The global vaccine market is substantial, driven by public health initiatives, increasing awareness of vaccine-preventable diseases, and the aging global population, which is more susceptible to certain infections. PREVNAR 13's established efficacy and safety profile have solidified its market share.
In the pediatric segment, PREVNAR 13 competes with other pneumococcal vaccines, notably those from Merck & Co. (Pneumovax 23 for adults and older children) and potentially newer entrants or vaccines with different serotype coverage. However, for the infant immunization schedule, PREVNAR 13 has been a cornerstone in many countries.
In the adult market, PREVNAR 13 competes with its predecessor, Pneumovax 23 (PPSV23), and more recently, with newer vaccines like Pfizer's own PREVNAR 20. Regulatory bodies and advisory committees, such as the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) in the United States, influence prescribing patterns through their vaccination recommendations. These recommendations often guide healthcare providers and payers, directly impacting product uptake and market penetration.
How has PREVNAR 13 performed financially?
PREVNAR 13 has been a significant revenue generator for Pfizer. The vaccine has consistently been one of the company's top-selling products for many years.
Revenue Performance (USD Millions)
| Year |
PREVNAR 13 Revenue |
| 2017 |
6,024 |
| 2018 |
5,755 |
| 2019 |
5,930 |
| 2020 |
5,941 |
| 2021 |
6,115 |
| 2022 |
5,773 |
| 2023 |
4,953 |
Source: Pfizer Inc. Annual Reports (2017-2023) [1, 2, 3, 4, 5, 6, 7]
The revenue figures illustrate a period of strong, relatively stable performance, with peaks and minor fluctuations. The slight decline in 2022 and a more pronounced decrease in 2023 reflect evolving market dynamics, including the introduction of competing products and potential shifts in vaccination strategies.
The global reach of PREVNAR 13 has been critical to its financial success. The vaccine is marketed in numerous countries worldwide, with sales driven by both public immunization programs and private healthcare markets. Reimbursement policies and government procurement contracts play a crucial role in its sales volume.
What are the key drivers of PREVNAR 13's market success?
Several factors have contributed to PREVNAR 13's market success:
- Broad Serotype Coverage: The 13-valent formulation provides protection against a wider range of Streptococcus pneumoniae serotypes compared to earlier vaccines like pneumococcal conjugate vaccine heptavalent (PCV7). This expanded coverage is a significant clinical and market advantage.
- Efficacy and Safety Profile: Extensive clinical trials and real-world evidence have demonstrated PREVNAR 13's efficacy in preventing invasive pneumococcal disease and pneumonia in both children and adults. Its well-established safety profile supports its widespread adoption.
- Inclusion in National Immunization Programs (NIPs): The recommendation and inclusion of PREVNAR 13 in the routine infant immunization schedules of major countries, including the United States, European Union member states, and many others, has been a primary driver of its volume and revenue. These NIPs ensure broad, consistent demand.
- Adult Vaccination Recommendations: Recommendations from bodies like the CDC ACIP for its use in adults aged 50 years and older, and in specific high-risk adult populations, have opened up a substantial market beyond pediatrics.
- Global Market Penetration: Pfizer's robust global supply chain and marketing infrastructure have facilitated widespread availability and adoption of PREVNAR 13 across diverse geographical regions.
- Limited Direct Competition (Historically): For a significant period, PREVNAR 13 faced limited direct competition in the pediatric conjugate vaccine space with equivalent serotype coverage.
What are the current challenges and future outlook for PREVNAR 13?
The market landscape for PREVNAR 13 is evolving, presenting several challenges and influencing its future trajectory.
- Competitive Landscape Evolution: The most significant challenge is the introduction of next-generation pneumococcal vaccines. Pfizer itself has launched PREVNAR 20, a 20-valent conjugate vaccine offering broader serotype coverage for both pediatric and adult use. Competitors also have newer vaccines in development or on the market.
- PREVNAR 20: This vaccine targets 20 serotypes, including 7 additional serotypes not covered by PREVNAR 13. Its approval for pediatric use in various regions creates direct competition within Pfizer's own portfolio and for the broader market.
- Other Competitors: Companies like Merck & Co. and others are also active in the pneumococcal vaccine space, developing or marketing vaccines with varying serotype coverage.
- Shifting Vaccination Guidelines: Advisory bodies periodically review and update vaccination recommendations based on new scientific evidence, disease epidemiology, and the availability of newer vaccines. These updates can lead to a transition from PREVNAR 13 to newer products, especially in NIPs. For example, recommendations may shift towards higher valency vaccines for both primary infant series and adult booster doses.
- Patent Expirations and Generic Competition: While the primary patents for PREVNAR 13 have expired or are nearing expiration in key markets, the complex manufacturing and regulatory pathways for vaccines can create a longer runway before direct generic competition significantly impacts sales. However, the threat of biosimilar or generic vaccine entry increases over time.
- Declining Efficacy Against Emerging Serotypes: As vaccination rates with PREVNAR 13 increase, there can be a selection pressure favoring non-vaccine serotypes, leading to an increase in diseases caused by these serotypes over time. This epidemiological shift can drive the demand for vaccines with broader serotype coverage.
- Supply Chain and Manufacturing Complexity: The production of complex biological products like vaccines requires significant investment and sophisticated manufacturing capabilities. Maintaining consistent supply and quality is paramount.
The future outlook for PREVNAR 13 will likely involve a gradual decline in market share as newer, broader-coverage vaccines are adopted by healthcare systems and recommended by public health authorities. Pfizer's strategy appears to be a managed transition, with PREVNAR 20 positioned as its next-generation pneumococcal vaccine. Nonetheless, due to its established presence, existing vaccination schedules, and cost-effectiveness in certain markets, PREVNAR 13 is expected to remain a relevant product for some time, particularly in regions where the adoption of newer vaccines is slower or where existing supply agreements are in place.
What is the regulatory landscape surrounding PREVNAR 13?
PREVNAR 13 has undergone rigorous regulatory review and approval processes in numerous countries by leading health authorities.
- U.S. Food and Drug Administration (FDA): Approved for pediatric use in 2010 and for adults aged 50 and older in 2012. Subsequent approvals have expanded its use and indication updates.
- European Medicines Agency (EMA): Received marketing authorization for pediatric and adult use in the European Union.
- Other National Regulatory Authorities: Approved by health ministries and regulatory bodies in Canada, Australia, Japan, and numerous other countries worldwide.
The regulatory framework for vaccines is characterized by stringent requirements for manufacturing quality, non-clinical and clinical safety and efficacy data, and post-market surveillance. Changes in regulatory recommendations, such as updated vaccination schedules or approvals of competing products, directly impact a vaccine's market position.
For instance, the CDC ACIP recommendations are influential. Initially, ACIP recommended PREVNAR 13 for infants and certain adults. Over time, ACIP recommendations have evolved, leading to discussions and potential shifts towards higher-valency vaccines.
Key Regulatory Milestones:
- 2010: FDA approval for pediatric use in the US [8].
- 2012: FDA approval for adults aged 50 years and older in the US [9].
- 2013: EMA approval for pediatric and adult use [10].
- Ongoing: Periodic reviews by regulatory bodies and advisory committees to update recommendations based on new data and epidemiological trends.
The patent landscape is also a critical component of the regulatory environment, defining the period of market exclusivity. While the core composition and manufacturing patents for PREVNAR 13 have expired or are expiring, the overall regulatory pathway for vaccines and the complexity of their production can influence the timing and impact of generic or biosimilar competition.
How does PREVNAR 13 compare to other pneumococcal vaccines?
PREVNAR 13's market position is best understood through direct comparison with other pneumococcal vaccines.
Comparison of Key Pneumococcal Vaccines:
| Vaccine Name |
Manufacturer |
Valency |
Target Population (Primary) |
Key Serotypes Covered (vs. PREVNAR 13) |
| PREVNAR 13 |
Pfizer |
13 |
Infants/Children & Adults |
Baseline (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F) |
| PREVNAR 20 |
Pfizer |
20 |
Infants/Children & Adults |
Includes all 13 serotypes of PREVNAR 13, plus 7 additional (8, 10A, 11A, 12F, 15B, 22F, 33F) [11] |
| Pneumovax 23 (PPSV23) |
Merck & Co. |
23 |
Adults (19+ years) & High-Risk Children (2+ years) |
Covers 23 serotypes, including all 13 from PREVNAR 13, plus 10 additional (2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 31, 33F) [12] |
| Synflorix |
GSK |
10 |
Infants/Children |
Covers 10 serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F) [13] |
Key Differentiating Factors:
- Valency: PREVNAR 13 offered a significant advancement in serotype coverage upon its introduction. PREVNAR 20 represents the next step in increasing this coverage, directly challenging PREVNAR 13's market segment. Pneumovax 23, while having the highest valency, is a polysaccharide vaccine and is not typically used for primary infant immunization due to lower immunogenicity.
- Target Population: PREVNAR 13 is indicated for both pediatric and adult use, providing a unified vaccine solution for different age groups. PREVNAR 20 also targets both populations. Pneumovax 23 is primarily for adults and specific high-risk groups. Synflorix is for pediatric use only.
- Mechanism: Conjugate vaccines like PREVNAR 13 and PREVNAR 20 induce T-cell dependent immune responses, leading to stronger and longer-lasting immunity, especially in young children. Polysaccharide vaccines like Pneumovax 23 induce T-cell independent responses, which are less robust in infants.
- Impact on Recommendations: The introduction of PREVNAR 20 by Pfizer and similar higher-valency vaccines by competitors has led to reviews and potential updates of vaccination guidelines. This is a critical factor in the ongoing transition within the pneumococcal vaccine market. For instance, in the US, the ACIP has moved towards recommending the use of 20-valent or 15-valent vaccines for adult pneumococcal vaccination in many scenarios.
This comparative analysis highlights that while PREVNAR 13 was a market leader due to its advanced serotype coverage and dual-population indication, it is now facing intensified competition from newer vaccines offering even broader protection.
Key Takeaways
PREVNAR 13 has been a commercially successful biologic drug for Pfizer, generating billions in revenue due to its broad serotype coverage, demonstrated efficacy, and widespread inclusion in national immunization programs for both pediatric and adult populations. Key drivers of its success included its clinical profile and limited competition in the conjugate vaccine space for many years. However, the market landscape is rapidly evolving with the introduction of next-generation pneumococcal vaccines, including Pfizer's own PREVNAR 20, which offer broader serotype protection. Shifting vaccination guidelines from advisory committees, the increasing threat of non-vaccine serotype disease, and the eventual impact of patent expirations are creating headwinds for PREVNAR 13. Its future trajectory will likely see a gradual decline in market share as healthcare systems and public health authorities transition to higher-valency vaccines.
Frequently Asked Questions
1. What is the primary mechanism of action for PREVNAR 13?
PREVNAR 13 is a pneumococcal 13-valent conjugate vaccine. It works by attaching the polysaccharide antigens from 13 different serotypes of Streptococcus pneumoniae to a carrier protein. This conjugation enhances the immune response, particularly in infants and young children, by converting the T-cell independent immune response to a T-cell dependent one, leading to robust antibody production and immunological memory.
2. When did PREVNAR 13 receive its initial approvals?
PREVNAR 13 received its first regulatory approval from the U.S. Food and Drug Administration (FDA) for pediatric use in February 2010. Subsequent approvals for adult use followed in various regions, including the FDA approval for adults aged 50 years and older in February 2012.
3. How does PREVNAR 13 address pneumococcal disease?
PREVNAR 13 protects against invasive pneumococcal disease (such as meningitis and bacteremia) and pneumonia caused by the 13 specific serotypes of Streptococcus pneumoniae included in the vaccine. It does not protect against serotypes not present in the vaccine or against diseases caused by other pathogens.
4. What is the current recommendation for PREVNAR 13 in the United States for adults?
Current recommendations from the CDC Advisory Committee on Immunization Practices (ACIP) for adults have evolved. For individuals aged 65 years and older who have not received pneumococcal vaccines, the recommendation is typically to receive a dose of either a 20-valent pneumococcal conjugate vaccine (like PREVNAR 20) or a 15-valent pneumococcal conjugate vaccine (like Vaxneuvance), or a dose of 13-valent pneumococcal conjugate vaccine (PREVNAR 13) followed by a dose of 20-valent pneumococcal conjugate vaccine (PREVNAR 20) at least one year later. For younger adults, specific indications apply, often favoring newer, higher-valency vaccines for initial vaccination in many scenarios.
5. What is the main difference between PREVNAR 13 and PREVNAR 20?
The primary difference between PREVNAR 13 and PREVNAR 20 lies in the number of Streptococcus pneumoniae serotypes they cover. PREVNAR 13 protects against 13 serotypes, while PREVNAR 20 protects against 20 serotypes. PREVNAR 20 includes all 13 serotypes covered by PREVNAR 13, plus seven additional serotypes that are also common causes of pneumococcal disease. This broader coverage is intended to provide enhanced protection against a wider range of invasive pneumococcal disease and pneumonia.
Citations
[1] Pfizer Inc. (2018). Annual Report on Form 10-K for the fiscal year ended December 31, 2017. U.S. Securities and Exchange Commission.
[2] Pfizer Inc. (2019). Annual Report on Form 10-K for the fiscal year ended December 31, 2018. U.S. Securities and Exchange Commission.
[3] Pfizer Inc. (2020). Annual Report on Form 10-K for the fiscal year ended December 31, 2019. U.S. Securities and Exchange Commission.
[4] Pfizer Inc. (2021). Annual Report on Form 10-K for the fiscal year ended December 31, 2020. U.S. Securities and Exchange Commission.
[5] Pfizer Inc. (2022). Annual Report on Form 10-K for the fiscal year ended December 31, 2021. U.S. Securities and Exchange Commission.
[6] Pfizer Inc. (2023). Annual Report on Form 10-K for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.
[7] Pfizer Inc. (2024). Annual Report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
[8] U.S. Food and Drug Administration. (2010, February 24). FDA approves new pneumococcal conjugate vaccine for infants and young children. FDA News Release.
[9] U.S. Food and Drug Administration. (2012, February 24). FDA approves Prevnar 13 to help prevent pneumococcal pneumonia and invasive disease in adults 50 years and older. FDA News Release.
[10] European Medicines Agency. (2013). Summary of Opinion: Prevenar 13. European Medicines Agency.
[11] Pfizer Inc. (2021, April 7). Pfizer’s Prevnar 20™ (20-valent pneumococcal conjugate vaccine) approved by the U.S. FDA for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults 18 years of age and older. Pfizer Press Release.
[12] Merck & Co., Inc. (2023). Prescribing Information: Pneumovax 23.
[13] GlaxoSmithKline. (2023). Synflorix Prescribing Information.
